| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
29,500,000 |
| Market
Cap: |
30.09(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.5405 - $2.16 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Quince Therapeutics is a clinical stage biopharmaceutical company focused on therapeutic approaches to improve the lives of patients diagnosed with Alzheimer's and degenerative diseases. Co.'s portfolio of gingipain inhibitors are orally administered, brain-penetrating small molecules. Co.'s pipeline includes proprietary drug candidates for the treatment of CNS disorders including Alzheimer's disease, for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of conditions like periodontitis. Co.'s pipeline also includes proprietary irreversible protease inhibitors under development for the treatment of coronavirus infection.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
241,811 |
990,009 |
| Total Buy Value |
$0 |
$0 |
$162,993 |
$1,072,009 |
| Total People Bought |
0 |
0 |
3 |
5 |
| Total Buy Transactions |
0 |
0 |
6 |
25 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-02-09 |
2024-11-08 |
2024-05-10 |
2023-05-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Thye Dirk |
CEO AND CHIEF MEDICAL OFFICER |
• • – |
2024-08-30 |
4 |
B |
$0.70 |
$53,900 |
D/D |
77,000 |
843,941 |
0.01 |
159% |
|
| Thye Dirk |
CEO AND CHIEF MEDICAL OFFICER |
• • – |
2024-08-29 |
4 |
B |
$0.69 |
$53,475 |
D/D |
77,500 |
766,941 |
0.01 |
171% |
|
| Hannah Brendan |
CHIEF BUSINESS OFFICER AND COO |
• – – |
2024-08-21 |
4 |
B |
$0.61 |
$19,337 |
D/D |
30,845 |
296,540 |
0.01 |
189% |
|
| Ryan Charles S. |
PRESIDENT |
• – – |
2024-08-20 |
4 |
B |
$0.65 |
$31,452 |
D/D |
48,387 |
122,461 |
0.01 |
216% |
|
| Hannah Brendan |
CHIEF BUSINESS OFFICER AND COO |
• – – |
2024-08-20 |
4 |
B |
$0.60 |
$3,579 |
D/D |
5,924 |
265,695 |
0.01 |
216% |
|
| Hannah Brendan |
CHIEF BUSINESS OFFICER AND COO |
• – – |
2024-08-19 |
4 |
B |
$0.58 |
$1,250 |
D/D |
2,155 |
259,771 |
0.01 |
187% |
|
| Hannah Brendan |
CHIEF BUSINESS OFFICER AND COO |
• – – |
2024-06-04 |
4 |
OE |
$0.55 |
$30,834 |
D/D |
56,061 |
257,616 |
|
- |
|
| Thye Dirk |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-01-16 |
4 |
OE |
$0.55 |
$190,791 |
D/D |
240,530 |
689,441 |
|
- |
|
| Lamond David |
Director |
– • – |
2023-12-14 |
4 |
B |
$1.04 |
$23,532 |
I/I |
22,627 |
2,347,545 |
2.1 |
3% |
|
| Lamond David |
Director |
– • – |
2023-12-13 |
4 |
B |
$1.00 |
$22,627 |
I/I |
22,627 |
2,324,918 |
2.1 |
4% |
|
| Lamond David |
Director |
– • – |
2023-12-12 |
4 |
B |
$1.02 |
$22,774 |
D/D |
22,327 |
2,302,291 |
2.39 |
6% |
|
| Lamond David |
Director |
– • – |
2023-12-12 |
4 |
B |
$1.00 |
$300 |
I/I |
300 |
2,279,964 |
2.02 |
6% |
|
| Lamond David |
Director |
– • – |
2023-12-07 |
4 |
B |
$1.01 |
$19,314 |
I/I |
19,123 |
2,279,664 |
2.1 |
5% |
|
| Lamond David |
Director |
– • – |
2023-12-06 |
4 |
B |
$1.02 |
$19,505 |
I/I |
19,123 |
2,260,541 |
2.1 |
6% |
|
| Lamond David |
Director |
– • – |
2023-12-05 |
4 |
B |
$1.01 |
$19,314 |
I/I |
19,123 |
2,241,418 |
2.1 |
3% |
|
| Lamond David |
Director |
– • – |
2023-12-01 |
4 |
B |
$0.94 |
$13,515 |
I/I |
14,378 |
2,222,295 |
2.1 |
-2% |
|
| Lamond David |
Director |
– • – |
2023-11-30 |
4 |
B |
$0.90 |
$12,940 |
I/I |
14,378 |
2,207,917 |
2.1 |
12% |
|
| Lamond David |
Director |
– • – |
2023-11-29 |
4 |
B |
$0.98 |
$14,090 |
I/I |
14,378 |
2,193,539 |
2.1 |
5% |
|
| Luca Benatti |
Director |
– • – |
2023-10-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
80,261 |
|
17% |
|
| Janhofer Guenter |
Chief Scientific OfficerOffice |
• – – |
2023-10-23 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
15,008 |
|
17% |
|
| Ryan Charles S. |
PresidentOfficer |
• – – |
2023-09-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
74,074 |
|
- |
|
| Lamond David |
Director |
– • – |
2023-08-31 |
4 |
B |
$1.32 |
$54,154 |
I/I |
41,026 |
2,179,161 |
2.1 |
-8% |
|
| Lamond David |
Director |
– • – |
2023-08-30 |
4 |
B |
$1.31 |
$53,744 |
I/I |
41,026 |
2,138,135 |
2.1 |
-12% |
|
| Lamond David |
Director |
– • – |
2023-08-17 |
4 |
B |
$1.29 |
$31,948 |
I/I |
24,766 |
2,097,109 |
2.1 |
-10% |
|
| Lamond David |
Director |
– • – |
2023-08-16 |
4 |
B |
$1.29 |
$151,379 |
I/I |
117,348 |
2,072,343 |
2.1 |
-12% |
|
119 Records found
|
|
Page 1 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.97%) 
